CAPTRUST Financial Advisors
EWTX icon

CAPTRUST Financial Advisors’s Edgewise Therapeutics EWTX Stock Holding History

CAPTRUST Financial Advisors’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$662K Buy
+16,288
New +$562K ﹤0.01% 1988
2022
Q3 		– Sell
-263
Closed -$2K – 2692
2022
Q2 		$2K Buy
+263
New +$1.99K ﹤0.01% 4449

Other funds holding EWTX

OrbiMed
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Paradigm Biocapital Advisors
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Jupiter Topco
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
Driehaus Capital Management
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Perceptive Advisors
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

CAPTRUST Financial Advisors's EWTX Position: Q2 2026 in Review

CAPTRUST Financial Advisors opened a new position in Edgewise Therapeutics (EWTX) in Q2 2026: 16,288 shares worth $662K. The stake represents ﹤0.01% of the portfolio and ranks #1988 among its holdings. This is a return to the name: CAPTRUST Financial Advisors previously reported a position in EWTX as recently as Q2 2022.

CAPTRUST Financial Advisors first reported a position in EWTX in Q2 2022 and has held it in 2 quarters since. 226 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • CAPTRUST Financial Advisors held 16,288 shares of Edgewise Therapeutics worth $662K as of Q2 2026.
  • Edgewise Therapeutics was a new CAPTRUST Financial Advisors position in Q2 2026.
  • Edgewise Therapeutics made up ﹤0.01% of CAPTRUST Financial Advisors's portfolio in Q2 2026, its #1988 holding.
  • CAPTRUST Financial Advisors first reported a position in Edgewise Therapeutics in Q2 2022 and has held it in 2 quarters since.
  • 226 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on CAPTRUST Financial Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.